


Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/579,007
				Filing Date	October 19, 2006
				First Named Inventor	Dennis L. Panicali
				Group Art Unit	1633
				Examiner Name	Anne Marie Sabrina Wehbe
				Attorney Docket Number	701278
Sheet	1	of	1	HHS Reference No.	E-088-2005/0-US-03

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation *
		Office	Application or Patent Number	Kind Code			

OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	A Z	APOSTOLOPOULOS et al., "Cellular Mucins: Targets for Immunotherapy," <i>Critical Reviews in Immunology</i> , 14: 293-309 (1994)	
	B A	KAUFMAN, et al., "Immunotherapy for pancreatic cancer: current concepts," <i>Hematol. Oncol. Clin. N. Amer.</i> , 16: 159-197 (2002)	
	B B	MARSHALL, John, "Carcinoembryonic Antigen-Based Vaccines," <i>Seminars in Oncology</i> , 30(3): 30-36 (2003)	
	B C	REYNOLDS, et al., "HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients," <i>Journal of Immunology</i> , 161: 6970-6976 (1998)	
	B D	WELLINGTON, et al., "Measles, Mumps, Rubella Vaccine (Priorix™, GSK-MMR) A Review of its Use in the Prevention of Measles, Mumps and Rubella," <i>Drugs</i> , 63 (19): 2107-2126 (2003)	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.